Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results high...
Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, conges...
HC Wainwright & Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Neutral and maintains $16...
Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(5.51) per share which beat the analyst consensus estimate of $(6...
-SEC Filing
